Brenig Therapeutics Initiates First-in-Human Trial of Brain-Selective NLRP3 Inhibitor BT-409 for Neurodegenerative Diseases
核心洞察
Brenig Therapeutics (搜索) has initiated a Phase 1 clinical trial of BT-409 (搜索), a novel brain-selective NLRP3 (搜索) inflammasome inhibitor designed using AI and machine learning platforms for neurodegenerative diseases (搜索).
The company plans to advance BT-409 (搜索) into proof-of-concept studies for Multiple Sclerosis (搜索) and Parkinson's disease (搜索) following successful Phase 1 completion.
Brenig also reported continued progress with BT-267, a brain-optimized LRRK2 (搜索) inhibitor, with Phase 1b and Phase 2 studies planned for early 2026 in Parkinson's disease (搜索) patients.
Brenig Therapeutics (搜索) has initiated a first-in-human clinical study of BT-409 (搜索), a novel brain-selective NLRP3 (搜索) inflammasome inhibitor, marking a significant milestone in the company's neurodegenerative disease pipeline. The clinical-stage biotechnology company also provided updates on its LRRK2 (搜索) inhibitor program, demonstrating continued advancement across multiple therapeutic targets.
Novel NLRP3 Inhibitor Enters Clinical Testing
BT-409 (搜索), licensed from Mwyngil Therapeutics (搜索), represents an innovative approach to targeting neuroinflammation (搜索) through selective NLRP3 (搜索) inflammasome inhibition. The small-molecule compound was discovered and optimized using a proprietary artificial intelligence and machine learning-enabled discovery platform, with specific design focus on central nervous system penetration, potency, and pharmacokinetic properties suitable for chronic neurologic indications.
The company has initiated a Phase 1 single ascending dose/multiple ascending dose study, with first dosing anticipated in early Q1 2026. The study is designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of BT-409 (搜索) in healthy volunteers.
"BT-409 (搜索) exemplifies our ability to design neuroinflammation (搜索)-targeting molecules with the selectivity and pharmacology required for neurodegenerative disease," said Megan McGill, MD, PhD, Chief Executive Officer of Brenig. "We are focused on translating this program efficiently into the clinic with the goal of delivering meaningful new treatment options for patients affected by neuroinflammatory and neurodegenerative diseases (搜索), and we look forward to exploring the potential of BT-409 across multiple neurologic indications."
Planned Expansion into Multiple Sclerosis and Parkinson's Disease
Subject to successful completion of Phase 1, Brenig plans to advance BT-409 (搜索) into proof-of-concept studies in Multiple Sclerosis (搜索) and Parkinson's disease (搜索). The studies will evaluate the therapeutic potential of central inflammasome inhibition in neuroinflammation (搜索) and neurodegeneration (搜索), including potential interactions with pathways involved in lysosomal and neuronal homeostasis.
LRRK2 Program Shows Promising Clinical Profile
Brenig reported continued progress in its clinical program for BT-267, a LRRK2 (搜索) inhibitor rationally designed to achieve robust CNS exposure while minimizing peripheral and systemic effects. Early clinical data demonstrate a favorable pharmacokinetic profile supporting sustained CNS exposure at levels predicted to exceed LRRK2 IC50 thresholds, with an encouraging safety and tolerability profile to date.
The company plans to initiate a Phase 1b study and commence start-up activities for a Phase 2 proof-of-concept trial of BT-267 in individuals with Parkinson's disease (搜索) in early 2026. BT-267 has been engineered for high brain permeability, potency, and selectivity—attributes believed to be critical for disease-modifying LRRK2 (搜索) inhibition in Parkinson's disease.
"The emerging clinical profile of BT-267 supports its potential as a best-in-class LRRK2 (搜索) inhibitor," said Tien Dam, MD, Chief Medical Officer of Brenig Therapeutics (搜索). "We believe CNS-optimized LRRK2 inhibition remains one of the most compelling therapeutic strategies in Parkinson's disease (搜索), and we are focused on advancing BT-267 efficiently into patient studies."
Company Background and Funding
Founded in 2021 through a venture creation initiative led by Torrey Pines Investment (搜索) and OrbiMed (搜索), Brenig Therapeutics (搜索) secured a $65 million Series A financing in July 2024, led by NEA (搜索) with participation from BioGeneration Ventures (搜索), OrbiMed, Torrey Pines, and other U.S.-based healthcare investors. The company is dedicated to developing innovative small-molecule therapies to address fundamental disease mechanisms and accelerate clinical translation for neurodegenerative diseases (搜索).